Literature DB >> 10516694

High-dose peripheral blood stem cell transplant for multitransfused severe aplastic anaemia patients without antithymocyte globulin in the conditioning regimen.

J Herrera-Garza1, J Jaime-Pérez, J Montemayor, R Ibarra-Peart, D Gómez-Almaguer.   

Abstract

Four multitransfused patients with severe aplastic anaemia (SAA) are described. Two received a BMT after conditioning with cyclophosphamide (Cy) plus antithymocyte globulin (ATG). Both suffered a graft failure (GF) and had a second transplant with PBSC from the original donor. Two other patients received a PBSCT as a first option, with Cy as the only conditioning drug. The four patients received methotrexate (MTX) and cyclosporine (CYA) as post-grafting immunosuppression. The two BMT patients with GF were successfully rescued with a PBSC second transplant. In the two cases where a PBSCT was done as a first option no GF was observed and a successful and complete haematological recovery was achieved. In conclusion, PBSCT rescued two SAA patients with GF after BMT. PBSCT without ATG as a first option produced a quick and complete haematological recovery in two additional patients, suggesting that PBSCT without ATG can be an alternative to BMT plus ATG in SAA as a first transplant option.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516694     DOI: 10.1038/sj.bmt.1701986

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  4 in total

1.  Cost structure and clinical outcome of a stem cell transplantation program in a developing country: the experience in northeast Mexico.

Authors:  José Carlos Jaime-Pérez; Alberto Carlos Heredia-Salazar; Olga G Cantú-Rodríguez; Homero Gutiérrez-Aguirre; César Daniel Villarreal-Villarreal; Consuelo Mancías-Guerra; José Luís Herrera-Garza; David Gómez-Almaguer
Journal:  Oncologist       Date:  2015-03-06

Review 2.  The simplification of the SCT procedures in developing countries has resulted in cost-lowering and availability to more patients.

Authors:  David Gómez-Almaguer
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia.

Authors:  Hubert Schrezenmeier; Jakob R Passweg; Judith C W Marsh; Andrea Bacigalupo; Christopher N Bredeson; Eduardo Bullorsky; Bruce M Camitta; Richard E Champlin; Robert Peter Gale; Monika Fuhrer; John P Klein; Anna Locasciulli; Rosi Oneto; Antonius V M B Schattenberg; Gerard Socie; Mary Eapen
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

4.  Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions.

Authors:  Rajat Kumar; Fumihiko Kimura; Kwang Woo Ahn; Zhen-Huan Hu; Yachiyo Kuwatsuka; John P Klein; Marcelo Pasquini; Koichi Miyamura; Koji Kato; Ayami Yoshimi; Yoshihiro Inamoto; Tatsuo Ichinohe; William Allen Wood; Baldeep Wirk; Matthew Seftel; Philip Rowlings; David I Marks; Kirk R Schultz; Vikas Gupta; Laurence Dedeken; Biju George; Jean-Yves Cahn; Jeff Szer; Jong Wook Lee; Aloysius Y L Ho; Anders Fasth; Theresa Hahn; Nandita Khera; Jignesh Dalal; Carmem Bonfim; Mahmoud Aljurf; Yoshiko Atsuta; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2016-01-18       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.